Elicio Therapeutics Inc. (NASDAQ: ELTX) announced the publication of research describing its AMP-DNA adjuvant candidates in the peer-reviewed journal Science Advances. The manuscript details preclinical studies of novel adjuvants built from the company's lymph node-targeting Amphiphile platform technology.

The published research, titled "Lymph node targeted DNA engages TBK1/IFN-I driven innate immunity to induce potent T cell responses and durable memory in mice and NHPs," examines the ability of AMP-DNA adjuvants to generate immune responses through targeted delivery to lymph nodes and activation of innate immune pathways.

According to the study findings, AMP-DNA adjuvants demonstrated superior performance compared to current clinical and commercial benchmark adjuvants in preclinical head-to-head comparisons. The research showed the adjuvants elicited antigen-specific CD8+ and CD4+ T cell responses and maintained immune memory for at least nine months in animal models.

The study included validation in non-human primates, where AMP-DNA induced T cell responses and neutralizing antibodies. The technology targets lymph nodes to create a localized immunostimulatory environment and operates through TBK1/IFN-I signaling pathways, which differs from the company's AMP-CpG technology that activates TLR-9.

"These data highlight our ability to precisely direct immune activation to the lymph nodes and unlock powerful, durable T cell responses through novel mechanisms, such as TBK1 and type I interferon signaling," said Peter DeMuth, Chief Scientific Officer of Elicio.

The research expands the scientific foundation of Elicio's AMP platform, which is designed to enhance immune responses by directing therapeutics to lymph nodes while minimizing systemic toxicity. The company is developing immunotherapies for cancer treatment, including its lead program ELI-002 targeting KRAS mutations.